Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Partners, RA Capital Management, Deerfield Management and Apple Tree Partners.
The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder.
Get the full story at our sister site, Drug Delivery Business News.
The post Braeburn raises $110m for opioid use disorder depot injection appeared first on MassDevice.